PAR

1.92%

25.5¢ paradigm biopharmaceuticals limited..

Where we at?, page-77

First 77 Last

Share
Profile

Follow
bobsee

233 Posts.

29

08/04/24

12:25

Post #: 73238063
Share

Originally posted by TanamiRod: ↑

Hey buck, nothing legally stopping Bene from buying PAR, but we don't really know their finances / ability to spend. What are global sales of Elmiron, maybe $300m, what are global sales of cartrophen, that is also not easy to establish and what is their cut on those sales (their cut from PAR is rumoured to be 3% ish).
Sure PAR represents major growth for Bene if they can get over hurdles and make it to the big stage, but at circa 3% royalty (Par to Bene) that's only $30m on $1bn in sales (you can all model it out to your hearts content: $2500 per course, 400,000 courses p.a. = $1bn in sales etc etc).
My point is they can sit this out and watch this management either get lucky or continue to blunder. If they get lucky, then great, Bene is a beneficiary, if they CONTINUE to blunder then they could purchase the IP if they so desire and waltz over to J&J and see if they can redeem themselves from the Elmiron troubles with a new application.
Bene have had ample time to dig into their pockets and become a shareholder or loan money to support trials, but they haven't, no-one from inside the healthcare community (corporate or investor) has decided to financially support PAR.

Expand

exactly ..... they are hoping we will run down to nothing because we are small and vulnerable.......and then easy pickings over the carcass...
get your act together PR...time is of the essence now......

PAR Price at posting: 33.0¢ Sentiment: Buy Disclosure: Held
9 Upvote

0 Great analysis

Reply

Top Stories

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

Microcap Wrap: 5 explorers with news out today

RCE

Recce's R327 found effective against E.coli during clinical trial

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

There are more pages in this discussion • 545 more messages in this thread...

First 77 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 25.5¢		Change -0.005(1.92%)		Mkt cap ! $89.19M

Open	High	Low	Value	Volume
27.0¢	27.0¢	25.5¢	$261.4K	990.7K

Buyers (Bids)

No.	Vol.	Price($)
1	9999	25.5¢

Sellers (Offers)

Price($)	Vol.	No.
26.0¢	9445	1

View Market Depth

No.	Vol.	Price($)
1	9999	0.255
5	259000	0.250
4	96000	0.245
9	261374	0.240
5	71970	0.235

Price($)	Vol.	No.
0.260	9445	1
0.275	44000	2
0.280	35900	3
0.285	6729	2
0.290	60000	2

Last trade - 16.10pm 28/06/2024 (20 minute delay)

PAR (ASX) Chart

Where we at?, page-77

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Ava Risk Group expands US presence with A$0.7M Substation Deal

Microcap Wrap: 5 explorers with news out today

Recce's R327 found effective against E.coli during clinical trial

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Where we at?, page-77

Top Stories

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Ava Risk Group expands US presence with A$0.7M Substation Deal

Microcap Wrap: 5 explorers with news out today

Recce's R327 found effective against E.coli during clinical trial

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News